Journal: Drug Development Research
Article Title: Cryptocaryone Exhibits ROS/MAPK‐Dependent Antiproliferative and Apoptosis‐Inducing Effects on Triple‐Negative Breast Cancer Cells and Proof‐of‐Concept Breast Cancer Mouse Model
doi: 10.1002/ddr.70286
Figure Lengend Snippet: Antiproliferative effects of CPC on TNBC cells in vitro and in vivo. (A) Cell viability of CPC and cisplatin in 24 h ATP assay. Two types of TNBC cells (MDA‐MB‐231 and HCC1937) and normal breast cells (M10) were included. Cells (left) were treated with 0 (vehicle control containing 0.1% DMSO), 0.5, 1.5, and 2 μg/mL of CPC for 24 h. Moreover, cells (right) were treated with 0, 0.5, 1.5, 2, 4, 6, 8, and 10 μg/mL of cisplatin for 24 h. (B) Recovery of CPC‐induced antiproliferation by NAC. Cells were pre‐incubated without or with NAC (10 mM for 1 h) and post‐incubated with CPC for 24 h (2 μg/mL), i.e., CPC and NAC/CPC. Columns labeled without overlapping letters in the same cell line differ significantly ( p < 0.05) (Tukey HSD post hoc test). Taking panel (B) as an example (MDA‐MB‐231 cells), the “a” (with overlapping letters) labeling the control, NAC, and NAC/CPC (0.5, 1.5, and 2) treatments indicates that their differences were non‐significant. In contrast, the “a, b, and c” (without overlapping letters) labeling the control, CPC 0.5, and CPC 1.5 μg/mL indicates significant differences in multi‐comparisons. Cell experimental data are displayed as means ± SD ( n = 3). (C) TNBC xenograft tumor suppression of CPC. MDA‐MB‐231‐xenografted mice were treated with CPC (0, 50, and 200 μg: CPC0, CPC50, and CPC200) for 5 weeks. Body weight and tumor volume were monitored twice weekly, and tumor weights were measured at 5 weeks. Animal experiment data are expressed as means ± SD ( n = 6).
Article Snippet: ATCC human TNBC cells (MDA‐MB‐231 and HCC1937) were included and maintained in mixed Dulbecco's Modified Eagle's Medium (DMEM)/F12 medium (3:2) and RPMI Medium 1640 (Gibco).
Techniques: In Vitro, In Vivo, ATP Assay, Control, Incubation, Labeling